Availability: Άμεσα Διαθέσιμο

Tumor Board Review Third Edition

Evidence-Based Case Reviews and Questions

ISBN: 9780826145970
Διαστάσεις 25 × 18 cm



Ημ. Έκδοσης





3η έκδοση

Κύριος Συγγραφέας

, ,

94,00€(Περιλαμβάνεται ΦΠΑ 6%)

Evidence-Based Case Reviews and Questions

Διαθεσιμότητα: 23-28 ημέρες


Now in its 3rd edition, Tumor Board Review: Evidence-Based Case Reviews and Questions is the most comprehensive clinical case review book in the field. With hands-on input from current fellows and oncologists, this new edition has been enhanced and reformatted for greater efficiency and practicality.

The review covers all disease-site areas in oncology and features a wide variety of board-style questions pivotal in helping fellows and oncologists prepare for both the ABIM medical oncology board exam and maintenance of certification (MOC) assessments. Evidence-based discussions of difficult patient cases offer an in-depth and accurate depiction of what is discussed at tumor boards and foster critical thinking essential for clinical practice. Patient cases also highlight impactful treatment decisions that include newly approved immunotherapies and targeted therapies. Each chapter contains digestible essentials for each case, including a summary of diagnosis, molecular and genomic testing, treatment options, toxicity considerations, follow-up, and survivorship. Each chapter ends with high-yield multiple-choice questions including answers and detailed rationales ensuring readers are well-equipped with the knowledge they need to make well-informed, individualized treatment decisions. Tumor Board Review: Evidence-Based Case Review and Questions is an essential case-based reference for anyone working in oncology.

Key Features:

  • Describes more than 120 patient cases, including locally advanced and metastatic cases for each major disease site
  • Contains 300 board-style questions and answers related to case reviews
  • Includes new advances in diagnosis and therapy, with a greater emphasis on immunotherapies, cancer genomics, and precision-based targeted therapies
  • Provides essentials for toxicity considerations, follow-up, and survivorship considerations


List of Contributors


Chapter 1. Head and Neck Cancer

Chapter 2. Thyroid Cancer

Chapter 3. Non-Small Cell Lung Cancer

Chapter 4. Small Cell Lung Cancer

Chapter 5. Hormone Receptor Positive Breast Cancer

Chapter 6. Triple Negative Breast Cancer

Chapter 7. Esophageal Cancer

Chapter 8. Gastric Cancer

Chapter 9. Pancreatic Cancer

Chapter 10. Neuroendocrine Cancer

Chapter 11. Hepatobiliary Cancer

Chapter 12. Colorectal Cancer

Chapter 13. Anal Cancer

Chapter 14. Prostate Cancer

Chapter 15. Testicular Cancer

Chapter 16. Renal Cancer

Chapter 17. Bladder Cancer

Chapter 18. Cervical Cancer

Chapter 19. Uterine Cancer

Chapter 20. Ovarian Cancer

Chapter 21. Melanoma

Chapter 22. Bone Sarcoma

Chapter 23. Soft Tissue Sarcoma

Chapter 24. Primary Brain Tumors

Chapter 25. Cancer Unknown Primary

Chapter 26. Hodgkin Lymphoma

Chapter 27. Non-Hodgkin Lymphoma

Chapter 28. Multiple Myeloma and Plasma Cell Neoplasms

Chapter 29. Acute Lymphoblastic Leukemia

Chapter 30. Acute Myelogenous Leukemia

Chapter 31. Chronic Myeloid Leukemia

Chapter 32. Chronic Lymphocytic Leukemia

Chapter 33. Myelodysplastic Syndrome